ApoB in Cardiovascular Risk Prediction

  • Jacqueline de Graaf
  • Patrick Couture
  • Allan D. Sniderman


In 2001, Adult Treatment Panel II (ATPII) added non-HDL-C as an alternative to LDL-C to estimate risk and to guide therapy in hypertriglyceridemic patients.193 In 2012 and 2013, first the European lipid guidelines194 and then the Canadian Guidelines195 confirmed LDL-C as the prime measure for clinical care but stated that non-HDL-C or apoB could be alternative measures to drive clinical decisions. In 2013, the ACC/AHA guidelines stated therapy should be based on regimens, not lipid targets, whereas in 2014, the Joint British Societies Guidelines (JBS3)196 and the National Lipid Association197 selected non-HDL-C as the preferred target of therapy.


Cardiovascular Risk Cholesterol Ester Transfer Protein VLDL Particle Accurate Marker Atherogenic Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Media BV, Houten, The Netherlands 2015

Authors and Affiliations

  • Jacqueline de Graaf
    • 1
  • Patrick Couture
    • 2
  • Allan D. Sniderman
    • 3
  1. 1.Department of Internal MedicineRadboud university medical centerNijmegenThe Netherlands
  2. 2.Lipid Research CentreLaval University Medical CenterQuebec CityCanada
  3. 3.Mike Rosenbloom Laboratory for Cardiovascular ResearchMcGill University Health CentreMontrealCanada

Personalised recommendations